1. Voors A, Koren M, Camacho A, Cleland J, Wagner F, Swart H, Pellicori P, Forgosh L, Gupta D, Karra R, Lund L, Hershberger R, Soloman R, Prasad N, Teichman S, Tamby J, Edelberg J, Yang C, Kelly C, Anderson R, Anto A, Kaylyn Bell,Fang Liang, Li W, del Rio C, Wells K, Henze M, Kurio G. Effects of danicamtiv, a novel cardiac myosin activator, in health failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. European Journal of Heart Failure. 19 June 2020.
2. Koren, M. J., Sabatine, M. S., Giugliano, R. P., Langslet, G., Wiviott, S. D., Ruzza, A., … Raal, F. J. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 29 October 2019. 74(17), 2132–2146.
3. Bruckert, E., Kereiakes, D. J., Koren, M. J., Louie, M. J., Letierce, A., Miller, K., & Cannon, C. P. PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. Journal of Clinical Lipidology. 2019 May- June. 13(3), 443–454.
4. Frias, J. P., Koren, M. J., Loizeau, V., Merino-Trigo, A., Louie, M. J., Raudenbush, M. A., & Batsu, I. The SYDNEY Device Study: A Multicenter, Randomized, Open-Label Usability Study of a 2-mL Alirocumab Autoinjector Device. Clinical Therapeutics. 2019 19 November.
5. Wasserman, S. M., Sabatine, M. S., Koren, M. J., Giugliano, R. P., Legg, J. C., Emery, M. G., … Gibbs, J. P. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. Journal of Cardiovascular Pharmacology and Therapeutics. 2018 16 May. 23(5), 423–432.
6. Koren, M. J., Sabatine, M. S., Giugliano, R. P., Langslet, G., Wiviott, S. D., Kassahun, H., … Raal, F. J. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiology. 2017 June. 2(6), 598–607.
7. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chirovolu P, Jackson S, Di M, Peach M, Somaratne R, Wasserman SM, Scott R, Stein EA; PCSK9 Inhibition-Mediated Reduction in Lp(a) with Evolocumab: an Analysis of 10 Clinical Trials and the LDL Receptor’s Role. Journal of Lipid Research. 2016 April 21. 57(6):1086-1096.
8. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 Apr 16;372(16):1500-9. Epub 2015 Mar 15.
9. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, Shahawy ME, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015 Apr 16;372(16):1489-99. Epub 2015 Mar 15.
10. Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J. 2015 Jun 21;36(24):1536-46. Epub 2015 Mar 23.
11. Koren MJ, Roth EM, McKenney JM, Gipe D, Hanotin C, Ferrand AC, Wu R, Dufour R. Safety and efficacy of alirocumab 150mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: a Phase II pooled analysis. Postgrad Med. 2015 Mar;127(2):125-32. Epub 2015 Jan 22.
12. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H; MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63(23):2531-40. Epub 2014 March 29.
13. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipodemia. N Engl J Med. 2014 May 29;370(19):1809-19. Epub 2014 Mar 29.
14. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huany F, Xue A, Albizem M, Scott R, Stein EA. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials. J Am Coll Cardiol. 2014 April 8;63(13):1278-88. Epub 2014 Feb 5.
15. Guyton JR, Bays H, Grundy SM, Jacobson TA. An Assessment by the Statin Intolerance Panel. Journal of Clinical Lipidology (2014) 8, S72-S81. 2014 March 4.
16. Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Mar 4. Epub 2014 Mar 4.
17. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H. Anti-PCSK9 Monotherapy for Hypercholesterolemia – The MENDEL-2 Randomized, Controlled Phase 3 Clinical Trial of Evolocumab. J Am Coll Cardiol. Epub 2014 Mar 25.
18. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS. Efficacy and safety of longer-term administration of Evolocumab (AMG 145) in patients with hypercholesterolemia: 52-Week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circ. 2014 Jan 19; 129(2):234-43. Epub 2013 Nov 19.
19. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomized, double-blind, placebo-controlled, phase 2 study. Lancet. 2012 Dec 8;380(9858):1995-2006. Epub 2012 Nov 6.
20. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380(9841):581-90. Epub 2012 May 17.
21. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy. J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53. Epub 2012 Mar 28.
22. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif JC, Rudd JH, Farkouh ME, Tawakol A; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomized clinical trial. Lancet. 2011 Oct 29;378(9802):1547-59. Epub 2011 Sep 9.
23. Koren MJ, Hamad A, Klasen S, Abeyratne A, McNutt BE, Kalra S. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia. Am J Health Syst Pharm. 2011 May 1;68(9):818-27.
24. Smith TR, Glazer RD, Koren MJ, Wernsing M, Zhang Y. Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomized, open-label, extension study. Int J Clin Pract. 2010 Sept;64(10):1367-74.
25. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 1;104(1):74-81.
26. Koren MJ, Feldman T, Medes RA. Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years. Clin Cardiol. 2009 May;32(5):256-63.
27. Kitay GS, Koren MJ, Helfet DL, Parides MK, Markenson JA. Efficacy of combined local mechanical vibrations, continuous passive motion and thermotherapy in the management of osteoarthritis of the knee. Osteoarthritis Cartilage. 209 Oct;17(10):1269-74. Epub 2009 May 3.
28. Koren MJ, Davidson MH, Wilson DJ, Fayyed RS, Zuckerman A, Reed DP, ALLIANCE Investigators. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009 May 11;53(5);741-50. Epub 2009 Feb 11.
29. Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R; FUSION II Investigators. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail. 2008 May;1(1):9-16.
30. Mullins CD, Rattinger GB, Kuznik A, Koren MJ. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: Economic analysis of the aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE) study. Clin Ther. 2008;30 Pt 2:2004-16.
31. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet; 371:117-25, 12 January 2008.
32. Straka RJ, Mamdani M, Damen J, Kuntze CE, Liu LZ, Batteman MF, Koren MJ. Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective. Curr Med Res Opin. 2007 Jul;23(7):1517-29.
33. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol, 2007 Mar 13;49(10);1027-34.
34. Parker JD, Bart BA, Webb DJ, Koren MJ, Siegel RL, Wang H, Malhotra B, Jen F, Glue P. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med. 2007 Aug;35(8):1863-8.
35. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006 Jun 7; 91(6); 2145-52. Epub 2006 Mar 7.
36. Koren MJ. Statin use is a “real-world” clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. Am J Med. 2005 Dec;118 Suppl12A:16-21.
37. Koren MJ, Hunninghake D, ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004 Nov 2;44(9):1772-79.
38. Bella JN, Palmieri V, Wachtell K, Liu JE, Gerdts E, Nieminen MS, Koren MJ, Zabalgoitia M, Wright JT, Dahlof B, Devereux RB. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. J Hum Hypertens. 2004 Jun;18(6):411-6.
39. Feldman T, Koren MJ, Insull W, McKenney J, Schrott H, Lewin A, Shah S, Sidisin M, Cho M, Kush D, Mitchel Y. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004 Jun 15;93(12):1481-6.
40. Hunninghake DB, McGovern ME, Koren MJ, Brazg R, Murdock D, Weiss S, Pearson T. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol. 2003 Mar;26(3):112-8.
41. Pepine CJ, Cooper-DeHoff RM, Weiss RJ, Koren MJ, CESNA-II study investigator group. Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. Am J Cardiol. 2003 Feb 1;91(3):274-9.
42. Koren MJ, Ulin R, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens. 2002 Dec;15(12):1021-1028.
43. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren MJ, Dinerman J, Silver M, Cheng ML. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Am Heart J. 2002 Dec;144(6):1102-1108.
44. Aurigemma GP, Devereux RB, DeSimone G, Roman MJ, O’Grady MJ, Koren MJ, Alderman M, Laragh J. Myocardial function and geometry in hypertensive subjects with low levels of afterload. Am Heart J. 2002 Mar;143(3):546-51.
45. Zabalgotitia M, Berning J, Koren MJ, Stoylen A, Nieminen M, Dahlof B, Devereux RB; LIFE Study Investigators. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertropy (the LIFE study). Am J Cardiol. 2001 Sep 15;88(6):646-50.
46. Insull W Jr, Koren M. Davignon J. Sprecher D, Schrott H, Keilson LM, Brown AS, Dujovne CA, Davidson MH, McLain R, Heinonen T. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis. 2001 July 1;157(1):137-44.
47. Turpie A, Gallus A, Hoek J, Pentasaccharide investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001 Mar 1;344(9):619-625.
48. Insull W, Koren MJ, Davignon J, Sprecher D, Schrott H, Keilson LM, Brown AS, Dujovne CA, Davison MH, McLain R, Heinonen T. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis. 2001;157(1):137-144.
49. Bella JN, Wachtell K, Palmieri V, Liebson PR, Gerdts E, Ylitalo A, Koren MJ, Pedersen OL, Rokkedal J, Dahlof B, Roman MJ, Devereux RB. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: The LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension Study. J Hypertens. 2001 Jan;19(1):127-34.
50. deSimone G, Palmieri V, Koren MJ, Mensah GA, Roman MJ, Devereux RB. Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension. J Hypertens. 2001 Jan;19(1):119-25.
51. Kjeldsen, E, and the LIFE Study Group. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens. 2000 Aug;13(8):899-906.
52. deSimone G, Roman MJ, Koren MJ, Mensah GA, Ganau A, Devereux RB. Stroke volume/pulse pressure ratio and cardiovascular risk in arterial hypertension. Hypertension. 1999 Mar;33(3):800-5.
53. Brown AS, Bakker-Arkema R, Yellen L, Henley RW, Guthrie R, Campbell CF, Koren MJ, Woo W, McLain R. Treating patients with documented atherosclerosis to NCEP-recommended LDL cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll of Cardiol. 1998 Sep;32(3):665-72.
54. Koren MJ, Smith DG, Hunninghake DB, Davidson MH, McKenney JM, Weiss SR, Schrott HG, Henley RW, Tresh P, McLain RW, Bakker-Arkema RG, Black DM. The cost of reaching national cholesterol education program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998 Jul;14(1):59-70.
55. PRISM Investigators (Platelet Receptor Inhibition in Ischemic Syndrome Management). A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998 May 21; 338(21):1498-1505.
56. McKenney JM, McCormick LS, Weiss S, Koren MJ, Kafonek S, Black DM for the Collaborative Atorvastatin Study Group. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am J Med. 1998 Feb;104(2):137-43.
57. Black D, Davidson M, Koren MJ, Bakker-Arkema R, Tresh P, McLain R, Smith D, Hunninghake D. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Pharmacoeconomics. 1997 Aug;12(2Pt2):278-285.
58. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. The Lancet. 1997 Aug 9;350(9075):389-96.
59. Cohen M, Demers C, Gurfinkel E, for the Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997 Aug 14;337(7):447-452.
60. Davidson M, McKenney J, Stein E, and the Atorvastatin Study Group. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997 Mar 1;87(5):674.
61. de Simone G, Devereux RB, Koren MJ, Casale PN, Laragh JH. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation. 1996 Jan 15;93(2):259-65.
62. Koren MJ, Bryant B, Hilton TC. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 1995 May 4;332(18):1237.
63. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995 Apr;25(5):1056-62.
64. Mensah GA, Pappas TW, Koren MJ, Ulin RJ, Laragh JH, Devereux RB. Comparison of classification of the severity of hypertension by blood pressure level and World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens. 1993 Dec;11(12):1429-40.
65. Koren MJ, Mensah GA, Blake J, Laragh JH, Devereux RB. Comparison of left ventricular mass and geometry between black and white patients with essential hypertension. Am J Hypertens. 1993 Oct; 6(10):815-23.
66. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991 Mar 1;114(5):345-52.
67. Pietronigro DD, McGinnis JE, Koren MJ, Crippa R, Seligman ML, Demopoulus HB. Spontaneous generation of Adriamycin free radicals at physiological pH. Physiologic Chem Physics 1979; 11(5):405

Review Articles:

1. Sabatine M, Underberg J, Koren M, Baum S. Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. Highlights from a CME symposium held at the Cardiometabolic Health Congress (CMHC) Sheraton Boston Hotel, Boston, MA, 23 Oct 2015. Postgrad Med J. 2016. Jul: 128(S1): 31-39.
2. Kopecky S, Baum S, Foody JM, Koren MJ, McKenney J, Sperling L, Wong ND. Insights Into Statin Intolerance. Clinical Cardiology. 2015 Sep;38(9):520-6. doi: 10.1002/clc.22432. Epub 2015 Sep 3
3. Koren MJ. Diastolic Congestive Heart Failure. Jacksonville Medicine, 2002 Feb;53(2):58-61.
4. Koren MJ. Health and Medical News: Heart and Circulatory System. In: Bahr, LS, ed. Health and Medical Year Book 1996. P. F. Collier, New York 1996:244-246.
5. Koren MJ. Health and Medical News: Heart and Circulatory System. In: Bloomfield L, ed. Health and Medical Year Book 1995. P.F. Collier, New York 1995:243-246.
6. Koren MJ. Health and Medical News: Heart and Circulatory System. In: Bloomfield L, ed. Health and Medical Year Book 1994. P.F. Collier, New York 1994:242-244.
7. Devereux RB, Koren MJ, DeSimone G, Okin PM, Kligfield P. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. European Heart Journal 1993;14(Suppl D):8-15.
8. Devereux RB, DeSimone G, Koren MJ, Mensah GA, Roman MJ. Left ventricular hypertrophy and hypertension. Clin Exp Hypertens. 1993 Nov;15(6):1025-32.
9. Koren MJ, Devereux RB. Hypertension and left ventricular hypertrophy: a consideration of current antihypertensive therapies. Nephrology Dialysis Transplantion 1993.
10. Devereux RB, Koren MJ, Roman M, Laragh JH. Left ventricular mass as a measure of pre-clinical disease in patients with hypertension. In: Multiple Risk Factors In Cardiovascular Disease. Kluwer Publishers, Boston 1993 pg 209-214.
11. Koren MJ, Kazakis DJ. Health and Medical News: Heart and Circulatory System. In: Bloomfield L, ed. Health and Medical Year Book 1993. P.F. Collier, New York 1993;pg 242-244.
12. Koren MJ, Devereux RB. Mechanism, effects and reversal of left ventricular hypertrophy in hypertension. Curr Opin Nephrol Hypertens. 1993 Jan;2(1):87-95.
13. Devereux RB, de Simone G, Ganau A, Koren MJ, Roman MJ. Left ventricular hypertrophy associated with hypertension and its relevance as a risk factor for complications. J Cardiovasc Pharmacol. 1993; 21(Suppl 2):S38-44.
14. Koren MJ, Fisher J. Health and Medical News: Heart and Circulatory System. In: Bloomfield L, ed. Health and Medical Year Book 1992. P.F. Collier, New York 1992;pg 285-289.
15. Devereux RB, de Simone G, Koren MJ, Roman MJ, Laragh JH. Left ventricular mass as a measure of pre-clinical hypertensive disease. Proceedings of the Sixth U.S. U.S.S.R. Symposium on Arterial Hypertension. Am J Hypertens. 1992 Jun; 5(6Pt2)175S-181S.
16. Devereux RB, deSimone G, Koren MJ, Roman MJ, Laragh JH. Left ventricular mass as a predictor of development of hypertension. Am J Hypertens. 1991 Nov;4(11):603S-607S.
17. Koren MJ, Devereux RB. Significance of left ventricular mass and geometry to morbidity and mortality in hypertensive men and women. Cardiology Board Review 1991,8(12):92-8.
18. Koren MJ, Devereux RB. Morbidity and mortality in uncomplicated essential hypertension. Cardiology Board Review 1991;8(12):92-98.
19. Koren MJ, Fisher J. Health and Medical News: Heart and Circulatory System. In: Bloomfield L, ed. Health and Medical Horizons 1991. Macmillan Educational Company, New York 1991;pg 287 291.
20. Koren MJ, Fisher J. Congestive Heart Failure. In: Bloomfield L, ed. Health and Medical Horizons 1991. Macmillan Educational Company, New York 1991;pg 210 212.
21. Koren MJ, Devereux RB. Risk, recognition and reversal of left ventricular hypertrophy in hypertension. Current Opinion in Cardiology 1991, 6:710-715.
22. Koren MJ, Fisher J. Health and Medical News: Heart and Circulatory System. In: Adolph T, ed. Health and Medical Horizons 1990. Macmillan Educational Company, New York 1990;pg 285 289.

1. Koren, MJ, Kereiakes, D, Pourfarzib, R, Winegar, D, Banerjee, P, Hamon, S, Hanotin, C, McKenney, JM. Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy. Journal of the American Heart Association. 2015 Sep 4 (11): 1-9.
2. Baum SJ, Knowles JW, Koren MJ, Moriarty PM, Watson KE. Promise of PCSK9 inhibitors brings hope to patients with familial hypercholesterolemia. Cardiology Today. 2015 Feb;18(2):10-12.
3. Koren MJ, Koski G, Reed DP, Rheinstein PH, Seltzer J, Silva H, Simha S, Stonier P. Statement of Clinical Investigator Competence. The Monitor. 2011 Aug;25(4): 79-82.

1. Garrelfs S, Frishberg Y, Hulton S, Koren M, O’Riordan W, Cochat P, Deschenes G, Shasha-Lavsky H, Saland J, van’t Hoff W, Fuster D, Magen D, Moochhala, S Schalk G, Simkova E, Groothoff J, Sas D, Meliambro K, Lu J, Garg P. “ILLUMINATE-A, a Phase 3 Study of Lumasiran, an Investigational RNAi Theraputic, in Children and Adults with Primary Hyperoxaluria Type 1 (Ph1).” Presented at the Regional Italian National Nephrology Society (SIN)2020 Congress. October 8-10, 2020.
2. Garrelfs S, Frishberg Y, Hulton S, Koren M, O’Riordan W, Cochat P, Deschenes G, Shasha-Lavsky H, Saland J, van’t Hoff W, Fuster D, Magen D, Moochhala, S Schalk G, Simkova E, Groothoff J, Sas D, Meliambro K, Lu J, Garg P. ILLUMINATE-A, une étude de phase 3 du lamasiran, un ARNi thérapeutique experimental, chez les enfants et adultes atteints d’hyperoxalurie primaire de type 1. Presented at the 25th Clinical- Biological Confrontations on Urinary Lithasis meeting in Paris, France. October 6-9, 2020
3. Koren M, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJ. Final Report of the OSLER-1 Study Long-term Evolocumab for the Treatment of Hypercholesterolemia. Presented at National Lipid Association Meeting. Miami, FL. May 16-19, 2019
4. Depre C, Starling A, Koren M, Eisele O, Mikol D. A Randomised, Double-Blind, Placebo-Controlled Study of Erenumab Safety in Patients with Stable Angina. Presented at American Academy of Neurology Meeting. Los Angeles, CA. April 21-27, 2018
5. George RT, Abuhsira L, Stoughton S, She D, Jin C, Buss N, Bakker-Arkema R, Koren M, Hirshberg B. Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Recombinant Human Lecithin-Cholesterol Acyltransferase (MEDI6012) in Subjects with Stable Coronary Heart Disease. Presented at AHA Scientific Sessions 2017. Anaheim, CA. November 12, 2017
6. Gurbel P, Barish C, Fort JG, Koren MJ, McKenzie M, Tursi JP. Efficacy and Safety of PA32540 (Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg) in Patients With a History of Myocardial Infarction: Analyses From Two Phase 3 Clinical Trials. Presented at AHA Scientific Sessions 2016. New Orleans, LA. November 12-16, 2016.
7. Koren MJ, Cyrille M, Ma Y, Somaratne R, Bolognese M. Frequency of Statin Downtitration During Open Label Evolocumab Treatment in the OSLER-2 Study. Annual Canadian Cardiovascular Congress. Montreal, Canada. October 22, 2016.
8. Koren MJ, Cyrille M, Ma Y, Somaratne R, Bolognese M. Frequency of Statin Downtitration During Open Label Evolocumab Treatment in the OSLER-2 Study. 84th Annual EAS Congress. Innsbruck, Austria. May 29-June 1, 2016.
9. Fielding RA, Bhasin S, Basaria S, Storer T, Clark BC, Law T, Pahor M, Manini TM, Binder E, Liu C, Koren MJ, Gasparino E, Tiseo PJ, Ren H, Kao R, Banerjee P, Kovalenko P, Mellis S, Pordy R, Donahue S, Qian X. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Bioeffect of REGN1033/SAR391786 with and without Exercise in Healthy Subjects (NCT01910220). International Conference on Frailty & Sarcopenia Research (ICFSR), Boston, MA. April 23-25, 2015.
10. Stroes E, Robinson J, Raal F, Dufour R, Sullivan D, Blagden M, Kassahun H, Yang J, Wasserman SM, Koren M. Clinical Equivalence of Evolocumab Among Patient Subgroups in PROFICIO: a Pooled Analysis of 3146 Patients from Phase 3 Studies. ESC Congress. London, United Kingdom. August 29-September 2, 2015.
11. Koren M, Rosenson R, Khan B, Honarpour N, Elliott M, Somaratne R, Wasserman S, Stroes E. LDL Cholesterol Reduction in Elderly Patients with the PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of 1779 Patients in Phase 2, 3 and Open Label Extension Studies. American College of Cardiology. San Diego, CA. March 17, 2015.
12. Koren MJ, Giugliano R, Raal F, Sullivan D, Bolognese M, Langslet G, Civeira F, Lowy A, Somaratne R, Liu T, Wasserman S, Scott R, Sabatine M. Two Year Analysis of the Safety and Tolerability of Evolocumab: The OSLER-1 Study. American College of Cardiology. San Diego, CA. March 16, 2015.
13. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes E, Langslet G, Raal FJ, Shahawy ME, Koren MJ, Lepor N, Lorenzato C, Pordy R, Chaudhari U, Kastelein J. Long-term Safety, Tolerability And Efficacy of Alirobcumab Versus Placebo In High Cardiovascular Risk Patients: First Results From The ODYSSEY LONG TERM Study In 2,341 Patients. AHA Scientific Sessions. Chicago, IL. November 19, 2014.
14. Koren MJ, Blom D, Giugliano RP, Stroes E, Somaratne R, Lowy A, Monsalvo ML, Hsu HC, Wasserman SM, Scott R, Sabatine MS. Safety and Tolerability of Very Low LDL-C Levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145). AHA Scientific Sessions. Chicago, IL. November 18, 2014.
15. Krauss RM, Banerjee P, Hamon S, Hanotin C, Sasiela B, Koren MJ, McKenney JM. Alirocumab, a Fully Human Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9, and Its Effects on Lipoprotein Subfractions Determined by Ion Mobility. AHA Scientific Sessions. Chicago, IL. November 18, 2014.
16. Raal F, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Honarpur N, Wasserman SM, Xue A, Scott R, Stein EA. Long-Term Reduction in Lipoprotein (a) with the PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of 3278 Patients in Phase 2, 3, and Open Label Extension Studies. AHA Scientific Sessions. Chicago, IL. November 17, 2014.
17. Wasserman SM, Koren MJ, Giugliano RP, Gibbs JP, Legg J, Emery MG, Haughney PC, Liu T, Scott R, Sabatine MS. Evaluation of the Relationship Between Evolocumab 140 mg Every Two Weeks and 420 mg Monthly Dosing Regimens. AHA Scientific Sessions. Chicago, IL. November 17, 2014.
18. Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM. Effects of Alirocumab, a Fully Human Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9, on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance: Substudy of a randomized double-blind Phase II Clinical Trial. 63rd Annual Scientific Session & Expo, American College of Cardiology, Washington, DC. March 30, 2014.
19. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim J, Scott R, Wasserman S, Bays H. Efficacy and Safety of Evolocumab (AMG 145) Monotherapy Compared With Ezetimibe and Placebo in Hypercholesterolemic Subjects: A Phase 3 Randomized Clinical Trial. 63rd Annual Scientific Session & Expo, American College of Cardiology, Washington, DC. March 29, 2014.
20. Koren MJ, Giugliano RP, Raal F, Sullivan D, Bolognese M, Langslet G, Civeira F, Scott R, Somaratne R, Nelson P, Liu T, Wasserman SM, Sabatine MS. Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145 Versus Standard of Care in 1104 Patients: 52-week Results from the OSLER Study. AHA Scientific Sessions. Dallas, TX. November 18, 2013.
21. Koren MJ, Giugliano RP, Raal F, Sullivan D, Bolognese M, Langslet G, Civeira F, Nelson P, Xu F, Sabatine M. Safety, tolerability, and efficacy of long-term administration of AMG 145: preliminary results from the OSLER study. ESC Congress. Amsterdam, Netherlands. September 2, 2013.
22. Giugliano RP, Raal F, Koren MJ, Sullivan D, Roth EM, Weiss R, Somaratne R, Yang J, Sabatine MS, Stein EA. Safety of AMG 145, a fully human monoclonal antibody to PCSK9: Data from four phase 2 studies in 1314 patients. ESC Congress. Amsterdam, Netherlands. August 31, 2013.
23. Koren MJ. Efficacy and Safety of a Fully Human Monoclonal Antibody Against PCSK9 as Monotherapy for Hypercholesterolemia: Results from the MENDEL Study, a Global Phase 2 Trial of AMG145. Scientific Sessions 2012, American Heart Association, Los Angeles, CA. November 6, 2012.
24. Sonstein S, Koren MJ, Silva H, Daemen E. Aligning Competences for Clinical Investigators and the Clinical Research Team. ACRP 2012 Global Conference & Exhibition, Houston, TX. April 15, 2012.
25. McKenney J, Koren MJ, Kereiakes D, Hanotin C, Ferrand AC, Stein EA. A Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, REGN727/SAR236553, in Patients with Primary Hypercholesterolemia. 61st Annual Scientific Session & Expo, American College of Cardiology, Chicago, IL. March 26, 2012.
26. Neutel J, Rolston W, Maddock S, Goldsmith S, Koren M, Van Antwerp B, Burnett J, Lieu HD. Initial Experience with Subcutaneous Infusion of Cenderitide in Patients with Chronic Heart Failure. 61st Annual Scientific Session & Expo, American College of Cardiology, Chicago, IL. March 26, 2012.
27. Koren MJ. What Should Investigators Know and How Should They Learn It? ACRP 2011 Global Conference & Exhibition, Seattle, WA. May 2, 2011.
28. Buhler F, Kesselring G, Koren MJ, Silva H, Stoltz R. Roundtable: “Certification of Clinical Research Professionals-Pros and Cons”. ACRP 2011 Global Conference & Exhibition, Seattle, WA. May 1, 2011.
29. Kesselring G, Koren MJ, Sonstein S. Innovations in Clinical Research Education. ACRP 2011 Global Conference & Exhibition, Seattle, WA. May 1, 2011.
30. Koren MJ, Pierce CH. Good Clinical Practice (GCP) – Everything You Always Wanted to Know But Were Afraid to Ask! ACRP 2011 Global Conference & Exhibition, Seattle, WA. April 29, 2011.
31. Wilson DJ, Shepherd J, Pedersen T, Koren MJ, Breazna A. Intensive Atorvastatin Treatment Reduces Cardiovascular Events (CVE) in Those with Dyslipidemia, Coronary Heart Disease (CHD) and with Mild or More Advanced Chronic Kidney Disease (CKD): An Analysis of the TNT, IDEAL and ALLIANCE Trials. 60th Annual Scientific Session & Expo, American College of Cardiology, New Orleans, LA. April 3, 2011.
32. Koren MJ, Anderson DL, McIvor M. Ethical Considerations in Patient Recruitment. ACRP 2010 Global Conference & Exhibition, Tampa, FL. April 23-27, 2010.
33. Koren MJ. Fraudulent Activities in Clinical Trials – An Investigator’s Perspective. 45th Annual Meeting, Drug Information Association, San Diego, CA. June 21-25, 2009.
34. Koren MJ. The Fallibility of Feasibility. ACRP 2008 Global Conference & Exhibition, Boston, MA. April 25-29, 2008.
35. Koren MJ, Maccubbin D, Davidson M, Macdonell G, Mallick M, McCrary Sisk C, Ballantyne C, Paolini JF. Flushing Profile of Extended Release Niacin/Laropiprant Versus Gradually Titrated NiaspanTM in Patients with Dyslipidemia. 57th Annual Scientific Sessions, American College of Cardiology. March 31, 2008.
36. McKenney J, Bays H, Koren MJ, Ballantyne C, Maccubbin D, Mitchel Y, Betteridge A, Kuznetsova O, Sapre A, McCrary Sisk C, Paolini JF. Safety Profile of Extended-Release Niacin/Laropiprant in Patients with Dyslipidemia. 57th Annual Scientific Sessions, American College of Cardiology. March 31, 2008.
37. G.S Kitay, MJ Koren, DL Helfet, JA Markenson. Efficacy of Local Mechanical Vibrations, Continuous Passive Motion and Thermotherapy in the Management of Osteoarthritis of the Knee: A Prospective, Randomized, Controlled, Double Cross-Over Study. Annual European Congress of Rheumatology EULAR 2007 Barcelona, Spain, 13-16 June 2007.
38. Koren MJ. Lipid research & possible impact on existing guidelines: Impact of aggressive treatment with atorvastatin on renal function in managed care patients with coronary heart disease: The ALLIANCE Study. 54th Annual Scientific Sessions, American College of Cardiology. March 7, 2005.
39. Koren MJ, Hunninghake D. Comparison of outcomes in managed care patients with coronary heart disease treated aggressively in lipid lowering disease management clinics or with usual care – the ALLIANCE Study. Late Breaking Trials; 53rd Annual Scientific Sessions, American College of Cardiology. March 8, 2004.
40. Zabalgoitis M, Berning J, Koren MJ, et al. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy: Losartan Intervention For End-points (LIFE) study. Abstract #869-3 from ACC Meetings, Anaheim CA. JACC ABSTRACTS Hypertension, Vascular Disease and Prevention, February 2000:292A.
41. Burger, AJ, Dennish G, Dinerman J, Koren MJ, et al. Nesiritide therapy for decompensated CHF is not proarrhythmic. Abstract #1049-155 from ACC Meetings, Anaheim CA. JACC ABSTRACTS Cardiac Function and Heart Failure, February 2000: 172A.
42. Bella JN, Wachtell K, Yitalo A, Koren MJ,et al. Relations of left ventricular geometry and function to systemic hemodynamis: the LIFE study. Abstract #2341 from the 71st AHA Scientific Sessions, Dallas TX. Circulation (Supplement 1);October 27, 1998;98(17):1-445.
43. Koren MJ, Insull W, Davila M, et al. ACAT inhibitor avasimibe lowers VLDL and TG in patients with hypertriglyceridemia. Abstract #1243 from the 71st AHA Scientific Sessions, Dallas TX. Circulation (Supplement 1); October 27, 1998;98(17):1-240.
44. Koren MJ. The relative efficacy and safety of atorvastatin, fluvastatin, lovastatin, and simvastatin in reaching NCEP LDL-C goals: the Treat-to-Target Trial. (A Poster Session) 71st Scientific Sessions of the American Heart Association, Dallas, TX. November 9, 1998.
45. deSimone G, Devereaux, Koren MJ, et al. Inadequate, adequate and inappropriate left ventricular hypertrophy in arterial hypertension. Abstract (Oral/Slide) Presentations, 70th AHA Scientific Sessions, Orlando FL, November 10, 1997.
46. Koren MJ, Tresh P, Smith D, Black D. Cost of resource utilization of atorvastatin compared with fluvastatin, lovastatin and simvastatin in patients with risk factors for CHD. 11th Annual Symposium on Atherosclerosis, Paris.1997. Oct 6 {1.P.167).
47. Koren MJ, Tresh P, Smith D, et al. Comparison of cost of resource utilization with atorvastatin versus fluvastatin, lovastatin, and simvastatin in patients with CHD and/or PVD. Poster presentation at the International Symposium on Atherosclerosis – October 5-9, 1997; Poster 1.P.166; Paris, France.
48. Koren MJ, Bryant B, Hilton TC. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med; May 4,1995; 332(18):1237;correspondence 1237-8.
49. Hilton TC, Downing PD, Strickland D, Blackshear JL, Safford RE, Koren MJ. Results from a prospective multicenter registry of patients with intra aortic atherosclerotic debris identified by transesophageal echocardiography. Circulation. 1994; 90:I400.
50. de Simone G, Devereux RB, Koren MJ, Casale PN, Laragh JH. Depressed midwall left ventricular performance predicts cardiac death in arterial hypertension. J Am Coll Cardiol. 1994; 23:115a.
51. Mensah GA, Koren MJ, Ulin RJ, Pappas TW, Nicholson J, Laragh JH, Devereux RB. Stratification by level of echocardiographic left ventricular mass index identifies hypertensive patients at very high and very low risk for long-term complications. Circulation. 1992;86:i662.
52. Mensah GA, Pappas TW, Koren MJ, Laragh JH, Devereux RB. Classification of hypertension severity for predicting echocardiographic markers of adverse prognosis: blood pressure versus World Health Organization Criteria. J Am Coll Cardiol. 1992;19:86a.
53. Koren MJ, Ulin RJ, Laragh JH, Devereux RB. Reduction in left ventricular mass during treatment of essential hypertension is associated with improved prognosis. Am J Hypertens. 1991;4(5):1a.
54. Koren MJ, Mensah GA, Blake J, Laragh JH, Devereux RB. Determinants of abnormal left ventricular wall thickening in patients with essential hypertension. J Am Coll Cardiol. 1991;17:2701a.
55. Mensah GA, Koren MJ, Blake J, Laragh JH, Devereux RB. Comparison of left ventricular geometry and mass between black and white essential hypertension patients. J Am Coll Cardiol. 1991;17:71a.
56. Devereux RB, Koren MJ, Okin PM, Kligfield P. Usefulness of the electrocardiogram for detection of hypertensive cardiomyopathy. Proceedings of the XVII International Congress on Electrocardiography. Florence, Italy, September 1990. pg 35.
57. Koren MJ, Savage DD, Casale PN, Laragh JH, Devereux RB. Changes in left ventricular mass predict risk in essential hypertension. Circulation. 1990; 82(suppl III):III 29.
58. Koren MJ, Savage DD, Laragh JH, Devereux RB. Relation of hemodynamic parameters to prognosis in patients with essential hypertension. Am J Hypertens. 1990;3(5):13a.
59. Mensah GA, Koren MJ, Savage DD, Laragh JH, Devereux RB. Racial differences in left ventricular hypertrophy in essential hypertension. Am J Hypertens. 1990;3(5):13a.
60. de Simone G, Devereux RB, Koren MJ, Casale PN, Laragh JH. Blood viscosity is a risk factor for cardiovascular morbidity in arterial hypertension. Am J Hypertens. 1990;3:2a.
61. Koren MJ, Casale PN, Savage DD, Laragh JH, Devereux RB. Left ventricular geometry and cardiac risk factors define high and low risk subgroups among essential hypertensives. J Am Coll Cardiol. 1990;15(2):111a.
62. Koren MJ, Casale PN, Savage DD, Laragh JH, Devereux RB. Relation of left ventricular mass to prognosis in essential hypertension. Circulation. 1989;80(4):II 538.
63. Hartney TJ, Shapiro S, Jain KM, Simoni EJ, Sempos CT, Cooper RS, Landauer JA, Koren MJ, Rimm AA. The physicians health study: Aspirin for the primary prevention of myocardial infarction. (correspondence). N Engl J Med. 1988;318(14):924-926.
64. Koren MJ, Devereux RB, Pappas TW, Casale PN, Milner M, Savage DD, Laragh JH. Echocardiographic left ventricular mass predicts complications of hypertension in both men and women. Am J Hypertens. 1988;1(3):II 12a.3.
65. Koren MJ. Aspirin and Stroke (Correspondence). N Engl J Med. 1988;318(14):926
66. Koren MJ, Fineberg HV. Prophylaxis against acid aspiration syndrome during general anesthesia in obstetric patients: a cost effectiveness analysis. Med Decis Making. 1984;4:544.
67. Koren, M.J., Moriarty, P.M., Baum, S.J. et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med (2022). https://doi.org/10.1038/s41591-021-01634-w
68. Nissen SE, Wolski K, Balog C, et al. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA. 2022;327(17):1679–1687. doi:10.1001/jama.2022.5050
69. Koren, M.J., Moriarty, P.M., Baum, S.J. et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med 28, 96–103 (2022). https://doi.org/10.1038/s41591-021-01634-w
70. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. Edson D. Moreira, Jr., M.D., Ph.D., Nicholas Kitchin, M.D., Xia Xu, Ph.D., Samuel S. Dychter, M.D., Stephen Lockhart, D.M., Alejandra Gurtman, M.D., John L. Perez, M.D., Cristiano Zerbini, M.D., Michael E. Dever, M.D., Timothy W. Jennings, D.O., Donald M. Brandon, M.D., Kevin D. Cannon, M.D., Michael J. Koren, M.D., Douglas S. Denham, D.O., Mezgebe Berhe, M.D., M.P.H., David Fitz‑Patrick, M.D., Laura L. Hammitt, M.D., Nicola P. Klein, M.D., Ph.D., Haylene Nell, M.D., Georgina Keep, B.Sc., Xingbin Wang, Ph.D., Kenneth Koury, Ph.D., Kena A. Swanson, Ph.D., David Cooper, Ph.D., Claire Lu, Ph.D., Özlem Türeci, M.D., Eleni Lagkadinou, M.D., Ph.D., Dina B. Tresnan, D.V.M., Ph.D., Philip R. Dormitzer, M.D., Ph.D., Uğur Şahin, M.D., William C. Gruber, M.D., and Kathrin U. Jansen, Ph.D., for the C4591031 Clinical Trial Group*